| Name | Title | Contact Details |
|---|
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.
EHC Communicationsm Inc is a Dobbs Ferry, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Technology and Patent Research International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Patient Care Technology Systems is a Mission Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Beardsworth Consulting Group is a Flemington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.